Prognostic prediction value of pretreatment 18F-FDG PET/CT in pediatric neuroblastoma
10.3760/cma.j.issn.2095-2848.2018.01.008
- VernacularTitle:治疗前18F-FDG PET/CT显像对小儿神经母细胞瘤预后的预测价值
- Author:
Biao DU
1
;
Baoping LIU
;
Xingmin HAN
;
Ruihua WANG
;
Xinli XIE
;
Qiao RUAN
Author Information
1. 450052,郑州大学第一附属医院核医学科
- Keywords:
Neuroblastoma;
Child;
Prognosis;
Positron-emission tomography;
Tomography,X-ray computed;
Deoxyglucose
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2018;38(1):33-36
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the prognostic value of pretreatment 18F-fluorodeoxyglucose (FDG) PET/CT in pediatric neuroblastoma (NB).Methods Twenty-seven NB patients (18 males,9 females;average age (4.6±2.4) years) confirmed by pathology from June 2012 to November 2015 were retrospectively included.All patients had detailed clinical and follow up data.They underwent 18F-FDG PET/CT scan before any treatment,and the largest diameter of primary tumors,maximum standardized uptake value (SUVmax) of primary tumor (Tmax),SUVmax of liver (Lmax),Tmax/Lmax ratio,clinical staging,serum ferritin,serum lactate dehydrogenase (LDH) and serum neuron-specific enolase (NSE) were recorded as prognostic factors.Patients were followed up after treatment for 3-32 months (median:24 months).KaplanMeier survival analysis was used to analyze the influence of Tmax and Tmax/Lmax ratio on 2-year progression free survival (PFS).Cox regression analysis was used to comprehensive analyze the influence of various factors on PFS.Results Of the 27 patients,12(44.4％) experienced disease progression during the follow-up period.Univariate analysis showed that N-myc gene amplification,serum LDH,serum NSE,serum ferritin,the largest diameter of primary tumors,Tmax and Tmax/Lmax ratio were significant prognostic factors for 2-year PFS.The multivariate analysis showed that only the Tmax and Tmax/Lmax,ratio were independent prognostic factors for 2-year PFS.Conclusion 18F-FDG PET/CT can provide effective information on the prognostic information for pediatric NB patients.
